SCHEMBL30765657

SCHEMBL30765657

C[C@@H](Nc1cnc(N2CCOCC2)n(CC(=O)NCc2cc3cnccc3[nH]2)c1=O)c1coc(-c2ccccc2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.36
NAMPT P43490 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
NTRK1 P04629 2/20 0.34
MAPK1 P28482 2/20 0.33
CCNK O75909 1/20 0.33
CDK12 Q9NYV4 1/20 0.33
AKT1 P31749 3/20 0.33
TNKS O95271 1/20 0.32
TNKS2 Q9H2K2 1/20 0.32
NTRK3 Q16288 1/20 0.32
TP53 P04637 1/20 0.32
LMNA P02545 1/20 0.32
F3 P13726 1/20 0.32
PIK3CD O00329 2/20 0.32
PIK3CB P42338 2/20 0.32
AVPR1B P47901 1/20 0.32
CYP3A4 P08684 1/20 0.32
PIK3CA P42336 1/20 0.32
MASP2 O00187 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765781 0.86 F2 (0.33) F2NAMPTMAPK1F3TRPV1
SCHEMBL30765880 0.84 F3 (0.36) F2NTRK1NTRK3F3
SCHEMBL30765553 0.84 MAPK1 (0.37) F2NAMPTNTRK1MAPK1AKT1
SCHEMBL30765435 0.83 F2 (0.36) F2NAMPTNTRK1MAPK1AKT1
SCHEMBL30765552 0.83 LMNA (0.38) L3MBTL1MAPK1LMNAPIK3CDPIK3CB
SCHEMBL30765780 0.82 NAMPT (0.40) F2NAMPTNTRK1MAPK1CCNK
SCHEMBL30766040 0.80 F2 (0.36) F2NAMPTNTRK1MAPK1NTRK3
SCHEMBL30765915 0.79 SMN1; SMN2 (0.39) F2NAMPTCCNKCDK12AKT1
SCHEMBL30766047 0.78 ALDH1A1 (0.35) L3MBTL1MAPK1TP53LMNAPIK3CD
SCHEMBL30765509 0.78 LMNA (0.43) L3MBTL1MAPK1TP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed